Why Myriad Genetics (MYGN) Stock Is Up TodayShares of genetic testing company Myriad Genetics (
NASDAQ:MYGN)
jumped 2.5% in the afternoon session after the company announced it would present new data from eight studies at the 2025 San Antonio Breast Cancer Symposium.
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer SymposiumNew data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q3 Earnings?Myriad Genetics’s 38.9% return over the past six months has outpaced the S&P 500 by 24.6%, and its stock price has climbed to $7.21 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
1 Healthcare Stock with Promising Prospects and 2 We QuestionHealthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized strong financial performance,
and over the past six months, the industry’s 15.5% return has closely followed the S&P 500.
Why Myriad Genetics (MYGN) Stock Is Trading Lower TodayShares of genetic testing company Myriad Genetics (
NASDAQ:MYGN)
fell 6% in the afternoon session after the U.S. Food and Drug Administration (FDA) approved a competing blood-based test for prostate cancer from rival company Cleveland Diagnostics.
Myriad Genetics, Neogen, ICU Medical, HCA Healthcare, and Universal Health Services Stocks Trade Up, What You Need To KnowA number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies. These subsidies, which are government financial aids to help people pay for health insurance, are crucial for insurers as they maintain a stable customer base. An extension would ensure continued revenue for companies with significant exposure to the ACA marketplace. The news prompted a strong positive reaction from investors, with Centene (CNC) shares jumping as much as 8%, Molina Healthcare (MOH) rising over 3%, and Oscar Health (OSCR) soaring 18%. The potential for a two-year extension reduces regulatory uncertainty for the sector, which investors view as a significant positive for the industry's outlook.
Insulet, Guardant Health, agilon health, Evolent Health, and Myriad Genetics Stocks Trade Up, What You Need To KnowA number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
Why Myriad Genetics (MYGN) Stock Is Up TodayShares of genetic testing company Myriad Genetics (
NASDAQ:MYGN)
jumped 0.4% in the afternoon session after the company shared a positive outlook, projecting significant revenue from its hereditary cancer testing division and outlining its growth targets for the coming years. Myriad Genetics projected approximately $370 million in revenue from this testing segment for the year, accounting for about 45% of its total sales. The company also targeted a growth rate in the high single-digits to low double-digits over the next three to five years. To help achieve these goals, it was supported by a $35 million investment aimed at enhancing its commercial capabilities.
Q3 Earnings Roundup: Myriad Genetics (NASDAQ:MYGN) And The Rest Of The Therapeutics SegmentEarnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Myriad Genetics (
NASDAQ:MYGN) and its peers.
1 High-Flying Stock with Solid Fundamentals and 2 We QuestionExpensive stocks often command premium valuations because the market thinks their business models are exceptional.
However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.
Merck, Elanco, Myriad Genetics, Neogen, and Cigna Shares Are Soaring, What You Need To KnowA number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied.
This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia pulled back after SoftBank sold its stake. This "hurt the AI trade," dragging down related names like Micron and Oracle.
As capital left tech, it sought safety in "higher quality" defensive names. Health care giants like Merck, Amgen, and Johnson & Johnson saw significant buying, boosting the Dow.
Myriad Genetics to Participate in Upcoming Investor Healthcare ConferencesSALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (
NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences.
The Top 5 Analyst Questions From Myriad Genetics’s Q3 Earnings CallMyriad Genetics’ third quarter saw revenue and adjusted profit in line with Wall Street expectations, but the market reacted negatively due to ongoing challenges in average revenue per test and operational headwinds. Management cited continued strong volume growth in the oncology segment, particularly for its MyRisk hereditary cancer test, as a positive. CEO Samraat Raha noted, “MyRisk continues to see positive demand in the market and supports our profitable growth journey,” while also acknowledging the impact of payer mix and policy changes. The company faced pressure from reduced coverage for its GeneSight mental health test and a divested European business, but highlighted improved execution and stabilization in core test volumes.
Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual ConferenceSALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (
NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and reproductive genetic testing at the National Society of Genetic Counselors (NSGC) 44th Annual Conference. Myriad’s MyRisk® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel® Prenatal Screen and Foresight® Carrier Screen are among the products included in the new studies to be shared.
Why Myriad Genetics (MYGN) Stock Is Down TodayShares of genetic testing company Myriad Genetics (
NASDAQ:MYGN)
fell 19.3% in the morning session after it reported mixed third-quarter results that were overshadowed by a weak earnings outlook.
MYGN Q3 Deep Dive: Oncology Growth and Product Launches Offset Market HeadwindsGenetic testing company Myriad Genetics (
NASDAQ:MYGN) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 3.6% year on year to $205.7 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $823 million at the midpoint. Its non-GAAP profit of $0 per share was $0.01 above analysts’ consensus estimates.
Myriad Genetics’s (NASDAQ:MYGN) Q3 Earnings Results: Revenue In Line With Expectations But Stock DropsGenetic testing company Myriad Genetics (
NASDAQ:MYGN) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 3.6% year on year to $205.7 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $823 million at the midpoint. Its non-GAAP loss of $0 per share was $0.01 above analysts’ consensus estimates.
What To Expect From Myriad Genetics’s (MYGN) Q3 EarningsGenetic testing company Myriad Genetics (
NASDAQ:MYGN)
will be reporting results this Monday after the bell. Here’s what to expect.
